Clinical Proton MR Spectroscopy in Central Nervous System Disorders
Abstract
MR spectroscopy is used worldwide as an adjunct to MR imaging in several common neurologic diseases, including brain neoplasms, inherited metabolic disorders, demyelinating disorders, and infective focal lesions.
A large body of published work shows that proton (hydrogen 1 [1H]) magnetic resonance (MR) spectroscopy has evolved from a research tool into a clinical neuroimaging modality. Herein, the authors present a summary of brain disorders in which MR spectroscopy has an impact on patient management, together with a critical consideration of common data acquisition and processing procedures. The article documents the impact of 1H MR spectroscopy in the clinical evaluation of disorders of the central nervous system. The clinical usefulness of 1H MR spectroscopy has been established for brain neoplasms, neonatal and pediatric disorders (hypoxia-ischemia, inherited metabolic diseases, and traumatic brain injury), demyelinating disorders, and infectious brain lesions. The growing list of disorders for which 1H MR spectroscopy may contribute to patient management extends to neurodegenerative diseases, epilepsy, and stroke. To facilitate expanded clinical acceptance and standardization of MR spectroscopy methodology, guidelines are provided for data acquisition and analysis, quality assessment, and interpretation. Finally, the authors offer recommendations to expedite the use of robust MR spectroscopy methodology in the clinical setting, including incorporation of technical advances on clinical units.
© RSNA, 2014
References
- 1. . Selective volume method for performing localized NMR spectroscopy . U.S. patent 4,480,228 . 1984 .
- 2. . Volume selection for in vivo biological spectroscopy . In: Govil G, Khetrapal CL, Saran A , eds. Magnetic resonance in biology and medicine . New Delhi, India : McGraw Hill , 1985 ; 387 – 397 .
- 3. . Localized proton spectroscopy using stimulated echoes . J Magn Reson 1987 ; 72 ( 3 ): 502 – 508 .
- 4. . Cerebral metabolism in man after acute stroke: new observations using localized proton NMR spectroscopy . Magn Reson Med 1989 ; 9 ( 1 ): 126 – 131 .
- 5. . Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease . Magn Reson Med 1990 ; 14 ( 1 ): 154 – 159 .
- 6. . Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors . Radiology 1989 ; 172 ( 2 ): 541 – 548 .
- 7. . The trouble with spectroscopy papers . Radiology 1991 ; 181 ( 2 ): 344 – 350 .
- 8. . Impact of evidence-based medicine on magnetic resonance spectroscopy . NMR Biomed 2006 ; 19 ( 4 ): 476 – 483 .
- 9. . The efficacy of diagnostic imaging . Med Decis Making 1991 ; 11 ( 2 ): 88 – 94 .
- 10. . Proton NMR chemical shifts and coupling constants for brain metabolites . NMR Biomed 2000 ; 13 ( 3 ): 129 – 153 .
- 11. . In vivo NMR spectroscopy: principles and techniques . 2nd ed. Hoboken, NJ : Wiley , 2007 .
- 12. . Magnetic resonance spectroscopy in intracranial infection . In: Gillard JH, Waldman AD, Barker PB , eds. Clinical MR neuroimaging . 2nd ed . London, England : Cambridge University Press , 2010 ; 426 – 454 .
- 13. . Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy . Magn Reson Med 2003 ; 49 ( 2 ): 223 – 232 .
- 14. . Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients . Neurology 2005 ; 64 ( 3 ): 434 – 441 .
- 15. . Propylene glycol is essential in the LCModel basis set for pediatric 1H-MRS . J Comput Assist Tomogr 2005 ; 29 ( 1 ): 136 – 139 .
- 16. . Ethanol in human brain by magnetic resonance spectroscopy: correlation with blood and breath levels, relaxation, and magnetization transfer . Alcohol Clin Exp Res 2000 ; 24 ( 8 ): 1227 – 1235 .
- 17. . Resolution improvements in in vivo 1H NMR spectra with increased magnetic field strength . J Magn Reson 1998 ; 135 ( 1 ): 260 – 264 .
- 18. . Signal-to-noise ratio and spectral linewidth improvements between 1.5 and 7 Tesla in proton echo-planar spectroscopic imaging . Magn Reson Med 2006 ; 56 ( 6 ): 1200 – 1210 .
- 19. . Localized proton NMR spectroscopy in different regions of the human brain in vivo: relaxation times and concentrations of cerebral metabolites . Magn Reson Med 1989 ; 11 ( 1 ): 47 – 63 .
- 20. (1) and T (2) relaxation times of human brain metabolites at 3 Tesla . NMR Biomed 2001 ; 14 ( 5 ): 325 – 331 .
- 21. . Quantitative 1H-magnetic resonance spectroscopy of human brain: influence of composition and parameterization of the basis set in linear combination model-fitting . Magn Reson Med 2002 ; 48 ( 3 ): 440 – 453 .
- 22. . MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T . Magn Reson Med 2009 ; 61 ( 6 ): 1279 – 1285 .
- 23. . In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T . Magn Reson Med 2009 ; 62 ( 4 ): 868 – 879 .
- 24. . In vivo 1H NMR spectroscopy of the human brain at 9.4 T: initial results . J Magn Reson 2010 ; 206 ( 1 ): 74 – 80 .
- 25. . Localized 1H NMR spectroscopy in different regions of human brain in vivo at 7 T: T2 relaxation times and concentrations of cerebral metabolites . NMR Biomed 2012 ; 25 ( 2 ): 332 – 339 .
- 26. . Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro . J Neurochem 1992 ; 59 ( 1 ): 55 – 61 .
- 27. . Studies on the distribution of N-acetyl-L-aspartic acid in brain . J Biol Chem 1957 ; 224 ( 1 ): 41 – 45 .
- 28. . Immunohistochemical localization of N-acetylaspartate in rat brain . Neuroreport 1991 ; 2 ( 3 ): 131 – 134 .
- 29. . A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline . NMR Biomed 1991 ; 4 ( 2 ): 47 – 52 .
- 30. . Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders . AJNR Am J Neuroradiol 2007 ; 28 ( 10 ): 1843 – 1849 .
- 31. . Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo . Neuroreport 1996 ; 7 ( 8 ): 1397 – 1400 .
- 32. . Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy . Neuropediatrics 1998 ; 29 ( 5 ): 254 – 264 .
- 33. . Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements . Radiology 2008 ; 248 ( 1 ): 210 – 220 .
- 34. . Neurochemistry of drug action: insights from proton magnetic resonance spectroscopic imaging and their relevance to addiction . Ann N Y Acad Sci 2010 ; 1187 : 148 – 171 .
- 35. . Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy . AJR Am J Roentgenol 1991 ; 157 ( 5 ): 1073 – 1078 .
- 36. . Studies of acute ischemic stroke with proton magnetic resonance spectroscopy: relation between time from onset, neurological deficit, metabolite abnormalities in the infarct, blood flow, and clinical outcome . Stroke 1998 ; 29 ( 8 ): 1618 – 1624 .
- 37. . Cerebral lactate and N-acetyl-aspartate/choline ratios in asphyxiated full-term neonates demonstrated in vivo using proton magnetic resonance spectroscopy . Pediatr Res 1994 ; 35 ( 2 ): 148 – 151 .
- 38. . Pitfalls in lactate measurements at 3T . AJNR Am J Neuroradiol 2006 ; 27 ( 4 ): 895 – 901 .
- 39. . Proton MR spectroscopy of intracranial tumours: in vivo and in vitro studies . J Comput Assist Tomogr 1990 ; 14 ( 4 ): 497 – 504 .
- 40. . High-resolution 1H NMR spectroscopy studies of extracts of human cerebral neoplasms . Magn Reson Med 1992 ; 24 ( 1 ): 123 – 136 .
- 41. . Characteristic metabolic profiles revealed by 1H NMR spectroscopy for three types of human brain and nervous system tumours . NMR Biomed 1995 ; 8 ( 6 ): 253 – 264 .
- 42. . Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults? AJNR Am J Neuroradiol 2008 ; 29 ( 2 ): 366 – 372 .
- 43. . Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging . AJNR Am J Neuroradiol 2003 ; 24 ( 10 ): 1989 – 1998 .
- 44. . Multiproject-multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy . MAGMA 2009 ; 22 ( 1 ): 5 – 18 .
- 45. . Accurate classification of childhood brain tumours by in vivo ¹H MRS: a multi-centre study . Eur J Cancer 2013 ; 49 ( 3 ): 658 – 667 .
- 46. . Development of a decision support system for diagnosis and grading of brain tumours using in vivo magnetic resonance single voxel spectra . NMR Biomed 2006 ; 19 ( 4 ): 411 – 434 .
- 47. . 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas . Nat Med 2012 ; 18 ( 4 ): 624 – 629 .
- 48. . Prospective diagnostic performance evaluation of single-voxel 1H MRS for typing and grading of brain tumours . NMR Biomed 2012 ; 25 ( 4 ): 661 – 673 .
- 49. . Linear discriminant analysis of brain tumour 1H MR spectra: a comparison of classification using whole spectra versus metabolite quantification . NMR Biomed 2007 ; 20 ( 8 ): 763 – 770 .
- 50. . Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM . J Neurooncol 2009 ; 91 ( 3 ): 337 – 351 .
- 51. . Could assessment of glioma methylene lipid resonance by in vivo 1H-MRS be of clinical value? Br J Radiol 2003 ; 76 ( 907 ): 459 – 463 .
- 52. . Characterization of intracranial mass lesions with in vivo proton MR spectroscopy . AJNR Am J Neuroradiol 1995 ; 16 ( 8 ): 1593 – 1603 .
- 53. . Untreated pediatric primitive neuroectodermal tumor in vivo: quantitation of taurine with MR spectroscopy . Radiology 2005 ; 236 ( 3 ): 1020 – 1025 .
- 54. . Non-invasive detection of glycine as a biomarker of malignancy in childhood brain tumours using in-vivo 1H MRS at 1.5 Tesla confirmed by ex-vivo high-resolution magic-angle spinning NMR . NMR Biomed 2010 ; 23 ( 1 ): 80 – 87 .
- 55. . Correlation of magnetic resonance spectroscopic and growth characteristics within grades II and III gliomas . J Neurosurg 2007 ; 106 ( 4 ): 660 – 666 .
- 56. . Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma . J Neurooncol 2009 ; 92 ( 3 ): 401 – 415 .
- 57. . Proton magnetic resonance spectroscopy in differentiating glioblastomas from primary cerebral lymphomas and brain metastases . J Comput Assist Tomogr 2010 ; 34 ( 6 ): 836 – 841 .
- 58. . Quantitative short echo time 1H MRSI of the peripheral edematous region of human brain tumors in the differentiation between glioblastoma, metastasis, and meningioma . J Magn Reson Imaging 2012 ; 36 ( 5 ): 1072 – 1082 .
- 59. . Intraaxial brain masses: MR imaging–based diagnostic strategy—initial experience . Radiology 2007 ; 243 ( 2 ): 539 – 550 .
- 60. . 1H-MR spectroscopy in the human spinal cord . AJNR Am J Neuroradiol 2013 ; 34 ( 9 ): 1682 – 1689 .
- 61. . Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma . J Neurooncol 2011 ; 105 ( 2 ): 365 – 373 .
- 62. . Elevated citrate in pediatric astrocytomas with malignant progression . Neurooncol 2011 ; 13 ( 10 ): 1107 – 1117 .
- 63. . Magnetic resonance spectroscopy metabolite profiles predict survival in paediatric brain tumours . Eur J Cancer 2013 ; 49 ( 2 ): 457 – 464 .
- 64. . Phase II trial of radiosurgery to magnetic resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma multiforme . Int J Radiat Oncol Biol Phys 2012 ; 84 ( 3 ): 668 – 674 .
- 65. . Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas . Neuroimage 2004 ; 23 ( 2 ): 454 – 461 .
- 66. . Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy . Radiology 2009 ; 253 ( 3 ): 805 – 812 .
- 67. . Short echo time 1H-MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses . Magn Reson Med 2008 ; 59 ( 1 ): 1 – 6 .
- 68. . First intraoperative, shared-resource, ultrahigh-field 3-Tesla magnetic resonance imaging system and its application in low-grade glioma resection . J Neurosurg 2010 ; 112 ( 1 ): 57 – 69 .
- 69. . Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects . J Magn Reson Imaging 2012 ; 35 ( 1 ): 56 – 63 .
- 70. . Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy . Br J Cancer 2004 ; 90 ( 4 ): 781 – 786 .
- 71. . Distinction between glioma progression and post-radiation change by combined physiologic MR imaging . Neuroradiology 2010 ; 52 ( 4 ): 297 – 306 .
- 72. . Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas . J Clin Neurosci 2010 ; 17 ( 1 ): 50 – 53 .
- 73. . Magnetic resonance in preterm and term newborns: 1H-spectroscopy in developing human brain . Pediatr Res 1991 ; 30 ( 6 ): 574 – 578 .
- 74. . Age-dependent changes in localized proton and phosphorus MR spectroscopy of the brain . Radiology 1990 ; 176 ( 2 ): 509 – 515 .
- 75. . Multiple sclerosis in childhood: report of 15 cases . Brain Dev 1991 ; 13 ( 6 ): 410 – 416 .
- 76. . Magnetic resonance imaging’s role in the care of the infant at risk for brain injury . In: Perlman JM , ed. Neurology: neonatology questions and controversies . 2nd ed . Amsterdam, the Netherlands : Elsevier , 2013 .
- 77. . Persistent increases in cerebral lactate concentration after birth asphyxia . Pediatr Res 1998 ; 44 ( 3 ): 304 – 311 .
- 78. . Moderate hypothermia to treat perinatal asphyxial encephalopathy . N Engl J Med 2009 ; 361 ( 14 ): 1349 – 1358 .
- 79. . Magnetic resonance spectroscopy: basic principles and application in white matter disorders . In: van der Knaap MS, Valk J , eds. Magnetic resonance of myelination and myelin disorders . 3rd ed . Berlin, Germany : Springer , 2005 ; 859 – 880 .
- 80. . Localized proton magnetic resonance spectroscopy of brain disorders in childhood . In: Bachelard HS , ed. Magnetic resonance spectroscopy and imaging in neurochemistry. New York, NY : Plenum , 1997 ; 329 – 402 .
- 81. . Handbook of 1H NMR spectroscopy in inborn errors of metabolism: body fluid NMR spectroscopy and in vivo MR spectroscopy . 2nd ed. Heilbronn, Germany : SPS Verlagsgesellschaft , 2007 .
- 82. . Noninvasive detection of increased glycine content by proton MR spectroscopy in the brains of two infants with nonketotic hyperglycinemia . AJNR Am J Neuroradiol 1993 ; 14 ( 3 ): 629 – 635 .
- 83. . Regional variation in brain lactate in Leigh syndrome by localized 1H magnetic resonance spectroscopy . Ann Neurol 1991 ; 29 ( 2 ): 218 – 221 .
- 84. . Quantitative proton magnetic resonance spectroscopy of cerebral metabolic disturbances in patients with MELAS . Neuropediatrics 1999 ; 30 ( 5 ): 256 – 263 .
- 85. . Proton NMR spectroscopy of cerebral metabolic alterations in infantile peroxisomal disorders . J Comput Assist Tomogr 1992 ; 16 ( 3 ): 335 – 344 .
- 86. . In vivo pyruvate detected by MR spectroscopy in neonatal pyruvate dehydrogenase deficiency . AJNR Am J Neuroradiol 2003 ; 24 ( 7 ): 1471 – 1474 .
- 87. . SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy . Nat Genet 2009 ; 41 ( 6 ): 654 – 656 .
- 88. . Leukoencephalopathy with accumulated succinate is indicative of SDHAF1 related complex II deficiency . Orphanet J Rare Dis 2012 ; 7 ( 1 ): 69 .
- 89. . Intracerebral blood and MRS in neonatal nonketotic hyperglycinemia . Pediatr Neurol 2010 ; 42 ( 3 ): 219 – 222 .
- 90. . Localized 1H NMR spectroscopy in Canavan’s disease: a report of two cases . Magn Reson Med 1991 ; 19 ( 2 ): 439 – 445 .
- 91. . Creatine deficiency syndromes. GeneReviews 2009 . http://www.ncbi.nlm.nih.gov/books/NBK3794/. Updated August 18, 2011. Accessed April 27, 2012 .
- 92. . Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism . Lancet 1996 ; 348 ( 9030 ): 789 – 790 .
- 93. . Developmental progress and creatine restoration upon long-term creatine supplementation of a patient with arginine:glycine amidinotransferase deficiency . Mol Genet Metab 2012 ; 106 ( 1 ): 48 – 54 .
- 94. . Long-term follow-up and treatment in nine boys with X-linked creatine transporter defect . J Inherit Metab Dis 2012 ; 35 ( 1 ): 141 – 149 .
- 95. . X-linked creatine deficiency syndrome: a novel mutation in creatine transporter gene SLC6A8 . Ann Neurol 2002 ; 52 ( 2 ): 227 – 231 .
- 96. . Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartia . Biochem J 2010 ; 425 ( 1 ): 127 – 136 .
- 97. . Absence of N-acetylaspartate in the human brain: impact on neurospectroscopy? Ann Neurol 2001 ; 49 ( 4 ): 518 – 521 .
- 98. . Regional age dependence of human brain metabolites from infancy to adulthood as detected by quantitative localized proton MRS . Pediatr Res 1999 ; 46 ( 4 ): 474 – 485 .
- 99. . Quantitative in vivo brain magnetic resonance spectroscopic monitoring of neurological involvement in mucopolysaccharidosis type II (Hunter syndrome) . J Inherit Metab Dis 2010 ; 33 ( Suppl 3 ): 395 – 399 .
- 100. . MR spectroscopy–based brain metabolite profiling in propionic acidaemia: metabolic changes in the basal ganglia during acute decompensation and effect of liver transplantation . Orphanet J Rare Dis 2011 ; 6 : 19 .
- 101. . The incidence of traumatic brain injury among children in the United States: differences by race . J Head Trauma Rehabil 2005 ; 20 ( 3 ): 229 – 238 .
- 102. . Magnetic resonance spectroscopy predicts outcomes for children with nonaccidental trauma . Pediatrics 2010 ; 125 ( 2 ): 295 – 303 .
- 103. . Hypoxic encephalopathy after near-drowning studied by quantitative 1H-magnetic resonance spectroscopy . J Clin Invest 1996 ; 97 ( 5 ): 1142 – 1154 .
- 104. . Classification of childhood white matter disorders using proton MR spectroscopic imaging . AJNR Am J Neuroradiol 2008 ; 29 ( 7 ): 1270 – 1275 .
- 105. . Childhood white matter disorders: quantitative MR imaging and spectroscopy . Radiology 2006 ; 241 ( 2 ): 510 – 517 .
- 106. . Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy . Curr Opin Mol Ther 2008 ; 10 ( 5 ): 471 – 478 .
- 107. . Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy . Neurology 2002 ; 58 ( 6 ): 901 – 907 .
- 108. . Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation . Neuropediatrics 2003 ; 34 ( 5 ): 237 – 246 .
- 109. . Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo . J Neurol 1993 ; 241 ( 2 ): 68 – 74 .
- 110. . Metachromatic leukodystrophy: a scoring system for brain MR imaging observations . AJNR Am J Neuroradiol 2009 ; 30 ( 10 ): 1893 – 1897 .
- 111. . Brain N-acetylaspartate levels correlate with motor function in metachromatic leukodystrophy . Neurology 2010 ; 75 ( 21 ): 1896 – 1903 .
- 112. . Long-term neuroimaging follow-up on an asymptomatic juvenile metachromatic leukodystrophy patient after hematopoietic stem cell transplantation: evidence of myelin recovery and ongoing brain maturation . Am J Med Genet A 2012 ; 158A ( 1 ): 257 – 260 .
- 113. . Proton magnetic resonance spectroscopy in multiple sclerosis . Neuroimaging Clin N Am 2009 ; 19 ( 1 ): 45 – 58 .
- 114. . Detection of myelin breakdown products by proton magnetic resonance spectroscopy . Lancet 1993 ; 341 ( 8845 ): 630 – 631 .
- 115. . Correlation of diffusion and metabolic alterations in different clinical forms of multiple sclerosis. PLoS ONE 2012;7(3):e32525.
- 116. . MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter . Magn Reson Med 2005 ; 53 ( 2 ): 256 – 266 .
- 117. . Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability . Arch Neurol 2001 ; 58 ( 1 ): 65 – 70 .
- 118. . Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis . J Neurol 2002 ; 249 ( 10 ): 1382 – 1390 .
- 119. . Guidelines for using proton MR spectroscopy in multicenter clinical MS studies . Neurology 2007 ; 69 ( 20 ): 1942 – 1952 .
- 120. . Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter . Eur Radiol 2013 ; 23 ( 2 ): 528 – 540 .
- 121. . Quantitative proton MR spectroscopic imaging in acute disseminated encephalomyelitis . AJNR Am J Neuroradiol 2001 ; 22 ( 6 ): 1125 – 1130 .
- 122. . In vivo single-voxel proton MR spectroscopy in intracranial cystic masses . AJNR Am J Neuroradiol 1998 ; 19 ( 3 ): 401 – 405 .
- 123. . Higher succinate than acetate levels differentiate cerebral degenerating cysticerci from anaerobic abscesses on in-vivo proton MR spectroscopy . Neuroradiology 2004 ; 46 ( 3 ): 211 – 215 .
- 124. . Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease . Neurology 2010 ; 75 ( 19 ): 1702 – 1710 .
- 125. . Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease: a 1H MRS study . Neurology 2000 ; 55 ( 2 ): 210 – 217 .
- 126. . Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer’s disease . Lancet 2000 ; 355 ( 9216 ): 1696 – 1697 .
- 127. . Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status . Mov Disord 2010 ; 25 ( 9 ): 1253 – 1261 .
- 128. . Brain metabolite alterations and cognitive dysfunction in early Huntington’s disease . Mov Disord 2012 ; 27 ( 7 ): 895 – 902 .
- 129. . Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer’s disease . Neurobiol Aging 2007 ; 28 ( 9 ): 1330 – 1339 .
- 130. . Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment . Int Rev Neurobiol 2009 ; 84 : 105 – 131 .
- 131. . Reduced hippocampal glutamate in Alzheimer disease . Neurobiol Aging 2011 ; 32 ( 5 ): 802 – 810 .
- 132. . Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy . Cerebellum 2011 ; 10 ( 2 ): 208 – 217 .
- 133. . Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy . Radiology 1993 ; 187 ( 2 ): 433 – 437 .
- 134. . In vivo MR spectroscopy of human dementia . Neuroimaging Clin N Am 1998 ; 8 ( 4 ): 809 – 822 .
- 135. . MRS shows abnormalities before symptoms in familial Alzheimer disease . Neurology 2006 ; 66 ( 5 ): 718 – 722 .
- 136. . MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology . Neurology 2010 ; 75 ( 9 ): 771 – 778 .
- 137. . Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease . Am J Psychiatry 2003 ; 160 ( 11 ): 2003 – 2011 .
- 138. . High field 1H MRS of the hippocampus after donepezil treatment in Alzheimer disease . Prog Neuropsychopharmacol Biol Psychiatry 2008 ; 32 ( 3 ): 786 – 793 .
- 139. . Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease . Prog Neuropsychopharmacol Biol Psychiatry 2010 ; 34 ( 1 ): 104 – 110 .
- 140. . Early identification of refractory epilepsy . N Engl J Med 2000 ; 342 ( 5 ): 314 – 319 .
- 141. . Early versus late remission in a cohort of patients with newly diagnosed epilepsy . Epilepsia 2010 ; 51 ( 1 ): 37 – 42 .
- 142. . Epilepsy surgery utilization: who, when, where, and why? Curr Opin Neurol 2012 ; 25 ( 2 ): 187 – 193 .
- 143. . Rates and predictors of long-term seizure freedom after frontal lobe epilepsy surgery: a systematic review and meta-analysis . J Neurosurg 2012 ; 116 ( 5 ): 1042 – 1048 .
- 144. . Brain energy metabolism . London, England : Wiley , 1978 .
- 145. . Neurometabolism in human epilepsy . Epilepsia 2008 ; 49 ( Suppl 3 ): 31 – 41 .
- 146. . Temporal lobe epilepsy: qualitative reading of 1H MR spectroscopic images for presurgical evaluation . Radiology 2001 ; 218 ( 1 ): 144 – 151 .
- 147. . Magnetic resonance spectroscopy in temporal lobe epilepsy . Neurology 1994 ; 44 ( 8 ): 1411 – 1417 .
- 148. . Proton MR spectroscopy of metabolite concentrations in temporal lobe epilepsy and effect of temporal lobe resection . Epilepsy Res 2009 ; 83 ( 2-3 ): 168 – 176 .
- 149. . Application of volumetric MR spectroscopic imaging for localization of neocortical epilepsy . Epilepsy Res 2010 ; 88 ( 2-3 ): 127 – 138 .
- 150. . Selective homonuclear polarization transfer for spectroscopic imaging of GABA at 7T . Magn Reson Med 2013 ; 69 ( 2 ): 310 – 316 .
- 151. . The role of 1H magnetic resonance spectroscopy in pre-operative evaluation for epilepsy surgery: a meta-analysis . Epilepsy Res 2006 ; 71 ( 2-3 ): 149 – 158 .
- 152. . Temporal pole proton preoperative magnetic resonance spectroscopy in patients undergoing surgery for mesial temporal sclerosis . Neurosurg Focus 2012 ; 32 ( 3 ): E3 .
- 153. . J-refocused coherence transfer spectroscopic imaging at 7 T in human brain . Magn Reson Med 2010 ; 64 ( 5 ): 1237 – 1246 .
- 154. . Proton magnetic resonance spectroscopy in children with temporal lobe epilepsy . Ann Neurol 1996 ; 39 ( 1 ): 107 – 113 .
- 155. . Clinical MRI of acute ischemic stroke . J Magn Reson Imaging 2012 ; 36 ( 2 ): 259 – 271 .
- 156. . Changes in metabolites and tissue water status after focal ischemia in cat brain assessed with localized proton MR spectroscopy . Magn Reson Med 1994 ; 32 ( 6 ): 685 – 691 .
- 157. . Changes in N-acetyl-aspartate content during focal and global brain ischemia of the rat . J Cereb Blood Flow Metab 1995 ; 15 ( 4 ): 639 – 646 .
- 158. . MR spectroscopy in stroke . Br Med Bull 2000 ; 56 ( 2 ): 334 – 345 .
- 159. . Combined 1H MR spectroscopy and diffusion-weighted MRI improves the prediction of stroke outcome . Neurology 2000 ; 55 ( 4 ): 498 – 505 .
- 160. . Spectroscopic imaging of stroke in humans: histopathology correlates of spectral changes . Neurology 1992 ; 42 ( 7 ): 1349 – 1354 .
- 161. . Magnetic resonance techniques for the identification of patients with symptomatic carotid artery occlusion at high risk of cerebral ischemic events . Stroke 2000 ; 31 ( 12 ): 3001 – 3007 .
- 162. . Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 Tesla proton MRS. PLoS ONE 2012;7(1):e30918.
- 163. . Towards 1H-MRSI of the human brain at 7T with slice-selective adiabatic refocusing pulses . MAGMA 2008 ; 21 ( 1-2 ): 95 – 101 .
- 164. . Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts . NMR Biomed 2004 ; 17 ( 6 ): 361 – 381 .
- 165. . Vespa: integrated applications for RF pulse design, spectral simulation and MRS data analysis [abstr] . In: Proceedings of the Nineteenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine , 2011 ; 1410 .
- 166. . Automatic quantitation of localized in vivo 1H spectra with LCModel . NMR Biomed 2001 ; 14 ( 4 ): 260 – 264 .
- 167. . Optimized quantitative magnetic resonance spectroscopy for clinical routine . Magn Reson Med 2013 ; 70 ( 1 ): 25 – 32 .
- 168. . Reproducibility study of whole-brain 1H spectroscopic imaging with automated quantification . Magn Reson Med 2008 ; 60 ( 3 ): 542 – 547 .
- 169. . On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain . NMR Biomed 2000 ; 13 ( 1 ): 28 – 36 .
- 170. . Short TE single-voxel 1H-MR spectroscopy of hippocampal structures in healthy adults at 1.5 Tesla: how reproducible are the results? NMR Biomed 2005 ; 18 ( 3 ): 195 – 201 .
- 171. . Reproducibility of 3D proton spectroscopy in the human brain . Magn Reson Med 2002 ; 47 ( 3 ): 439 – 446 .
- 172. . Short echo time 1H MRSI of the human brain at 3T with adiabatic slice-selective refocusing pulses: reproducibility and variance in a dual center setting . J Magn Reson Imaging 2010 ; 31 ( 1 ): 61 – 70 .
- 173. . Test-retest reliability and reproducibility of short-echo-time spectroscopic imaging of human brain at 3T . Magn Reson Med 2011 ; 66 ( 2 ): 324 – 332 .
- 174. . Test-retest repeatability of human neurochemical profiles measured at 3 versus 7 T [abstr] . In: Proceedings of the Twentieth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine , 2012 ; 1739 .
- 175. . Short-echo, single-shot, full-intensity proton magnetic resonance spectroscopy for neurochemical profiling at 4 T: validation in the cerebellum and brainstem . Magn Reson Med 2011 ; 65 ( 4 ): 901 – 910 .
- 176. . Deriving biomedical diagnostics from NMR spectroscopic data . Biophys Rev 2011 ; 3 ( 1 ): 47 – 52 .
- 177. . Creating robust, reliable, clinically relevant classifiers from spectroscopic data . Biophys Rev 2009 ; 1 ( 4 ): 201 – 211 .
Article History
Received March 1, 2013; revision requested April 9; revision received July 30; accepted August 30; final version accepted August 27.Published online: Mar 2014
Published in print: Mar 2014